Collaborative Innovation in CDMOs: Interview Series with Pharmaceutical Technology
Part 1: Early Engagement, IP Strategy, and Advanced Formulation
In Part 1 of the interview series, Dr. Dave Miller Ph.D. (CSO) explores why engaging a CDMO at the earliest stages of development can unlock significant strategic advantages. Miller discusses how early collaboration enables stronger IP protection, informed formulation design, and alignment between clinical and commercial objectives. The piece highlights AustinPx’s ability to tailor solutions that anticipate regulatory, manufacturing, and market needs from the outset, helping sponsors avoid costly missteps and protect long-term asset value.
Part 2: The Importance for CDMOs of Partnering With a Sponsor’s Mindset
In this feature, Dr. Dave Miller Ph.D. (CSO) explains how AustinPx’s roots as a pharmaceutical sponsor shape its approach to partnerships. By thinking like a developer, the team prioritizes scientific depth, asset protection, and strategic alignment across the entire drug lifecycle. The article illustrates how this mindset builds stronger, more collaborative relationships that go beyond transactional services to deliver solutions that perform in the clinic, at market launch, and over the product’s lifetime.
Part 3: Onshoring’s Unexpected Benefits: Quality, Efficiency, and Supply Chain Resilience
In this part of the interview series, Dr. Dave Miller Ph.D. (CSO) explores how recent shifts toward onshoring are doing more than reshaping supply chains. The discussion highlights how closer-to-home manufacturing strengthens quality oversight, increases efficiency, and provides a more resilient response to global disruptions. Miller shares why the move to onshore partnerships is becoming a strategic advantage, not just a regulatory or geopolitical necessity.
Part 4: Sustainability Becomes Essential: Green Manufacturing and Supply Chain Resilience
Part four turns to the evolution of CDMO–sponsor relationships. Miller outlines how the best partnerships now extend far beyond transactional services, emphasizing lifecycle planning, shared accountability, and sponsor-informed decision-making. The conversation underscores how CDMOs that combine scientific depth with transparent collaboration are redefining what true partnership looks like in today’s complex drug development landscape.
Part 5: Intellectual Property as a Core Strategy in Drug Formulation and Development
In the series finale, Dr. Dave Miller Ph.D. (CSO) explores the critical role of intellectual property (IP) strategy in formulation development. He explains why IP should be embedded from the earliest stages of formulation planning, particularly for compounds nearing the end of their patent life cycles. By designing custom formulations that improve bioavailability, stability, and manufacturability, organizations can create new, patentable assets and sustain protection beyond traditional regulatory exclusivity. Proprietary platforms also provide a technological moat that helps protect clients from generic competition even after patents expire.